2021
Hematopoietic Cell Transplantation for Sickle Cell Disease
Krishnamurti L. Hematopoietic Cell Transplantation for Sickle Cell Disease. Frontiers In Pediatrics 2021, 8: 551170. PMID: 33469520, PMCID: PMC7813811, DOI: 10.3389/fped.2020.551170.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseAutologous hematopoietic progenitor cellsCell transplantationHematopoietic progenitor cellsDisease manifestationsCell diseaseRelated donor hematopoietic cell transplantationDonor hematopoietic cell transplantationEarly phase clinical trialsHaploidentical related donorsIntent of cureProgenitor cellsIschemic tissue damageLong-term ameliorationHaploidentical donorsEndothelial dysfunctionHLA-identicalLate complicationsRed blood cellsUnrelated HLAOrgan dysfunctionRelated donorsUnrelated donorsSCD patients
2005
Mixed Hematopoietic Chimerism for Sickle Cell Disease Prevents Intravascular Hemolysis and Corrects Biomarkers of Endothelial Function.
Wu C, Krishnamurti L, Gladwin M, Biernacki M, Rogers S, Wang X, Zahrieh D, Antin J, Ritz J. Mixed Hematopoietic Chimerism for Sickle Cell Disease Prevents Intravascular Hemolysis and Corrects Biomarkers of Endothelial Function. Blood 2005, 106: 2333. DOI: 10.1182/blood.v106.11.2333.2333.Peer-Reviewed Original ResearchSickle cell diseaseMixed hematopoietic chimerismStem cell transplantationEndothelial functionIntravascular hemolysisMixed chimerismPulmonary hypertensionDonor engraftmentCell transplantationVascular functionHematopoietic chimerismNonmyeloablative allogeneic stem cell transplantationChronic end-organ damageAllogeneic stem cell transplantationEnd-organ injuryExperienced graft rejectionEnd-organ damageEnd-organ toxicityPre-transplant levelsDonor cell engraftmentChronic intravascular hemolysisSuccess of therapyFree Hb concentrationEndothelial dysfunctionGraft rejection